Table 4.
Details of the included studies
| Author | n | SAE site (n) | SAE material (n) | Primary success [n(%)] | Severe complication [n(%)] | DC III [n(%)] | |||
|---|---|---|---|---|---|---|---|---|---|
| P | D | P + D | Coil | Gelfoam | |||||
| Niloy et al. [7] | 45 | 9 | 34 | 2 | 21 | 5 | 41 (91.1) | 13 (28.9) | 3 (6.7) |
| Liu et al. a [10] | 6 | 0 | 6 | 0 | 5 | 1 | 5 (83.3) | 0 (0) | 1 (16.7) |
| Ekeh et al. [11] | 88 | 51 | 22 | 15 | 88 | 0 | 84 (95.5) | 8 (9.1) | 0 (0) |
| Liu et al. [16] | 15 | - | - | - | 0 | 0 | 12 (80.0) | 1 (6.7) | 0 (0) |
| Franco et al. a[25] | 14 | 8 | 6 | 0 | 12 | 1 | 13 (92.9) | 1 (7.1) | 0 (0) |
| Wu et al. a[26] | 53 | 5 | 48 | 0 | 24 | 29 | 44 (83.0) | 14 (26.4) | 0 (0) |
| Smith et al.a [27] | 41 | 27 | 9 | 5 | 22 | 2 | 30 (73.0) | 12 (29.3) | 12 (29.3) |
| Haan et al.a [28] | 140 | - | - | - | 83 | 48 | 122 (87.1) | 38 (27.1) | 3 (2.1) |
| Ekeh et al. a[30] | 15 | 10 | 1 | 4 | - | - | 14 (93.3) | 1 (6.7) | 0 (0) |
| Wu et al.a [32] | 19 | 3 | 16 | 0 | 0 | 16 | 14 (74.0) | 7 (36.8) | 5 (26.3) |
| Edmund et al. [47] | 8 | 3 | 0 | 5 | - | - | 8 (100.0) | 1 (12.5) | 1 (12.5) |
| Ashraf et al. [48] | 109 | 109 | 0 | 0 | 109 | 0 | 102 (93.6) | 7 (6.4) | 0 (0) |
| Kaseje et al. [49] | 11 | 8 | 3 | 0 | - | - | 8 (72.7) | 3 (27.3) | 3 (27.3) |
| Haan et al. [50] | 32 | 32 | 0 | 0 | 32 | 0 | 29 (90.1) | 3 (9.4) | 3 (9.4) |
| Wu et al. [51] | 10 | 3 | 7 | 0 | 0 | 10 | 8 (80.0) | 9 (90.0) | 2 (20.0) |
| Bessoud et al. [52] | 37 | 37 | 0 | 0 | 37 | 0 | 36 (97.0) | 1 (2.7) | 1 (2.7) |
| Killeen et al.a [53] | 53 | 24 | 22 | 7 | - | - | 47 (88.7) | 43 (81.1) | 3 (5.7) |
| Sclafani et al. [54] | 60 | 60 | 0 | 0 | 60 | 0 | 57 (95.0) | 5 (8.3) | 3 (5.0) |
| Sclafani et al. [55] | 18 | 17 | 0 | 1 | 18 | 0 | 18 (100) | 1 (5.6) | 0 (0) |
| Gaarder et al. a[56] | 27 | 21 | 2 | 4 | - | - | 26 (96) | 1 (3.7) | 0 (0) |
| Cooney et al.a [57] | 9 | 6 | 3 | 0 | - | - | 6 (67) | 3 (33.3) | 0 (0) |
| Hagiwara et al. [58] | 15 | 9 | 1 | 5 | - | - | 15 (100) | 5 (33.3) | 1 (6.7) |
| Wei et al.[59] | 51 | 14 | 37 | 0 | - | - | 50 (98) | 2 (3.9) | 15 (29.4) |
| Total | 876 | 456 | 217 | 48 | 511 | 112 | 789 (90.1) | 179 (20.4) | 56 (6.4) |
aStudy in 2nd study set; SAE. Splenic artery embolization; P. Proximal splenic artery embolization; D. Distal splenic artery embolization; P + D: Combination of proximal and distal splenic artery embolization; DC III: Clavien-Dindo classification of morbidity for complication III; “-”Not mentioned